Trial Profile
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Saracatinib (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Therapeutic Use
- 22 Jul 2019 Primary endpoint (The effect of treatment with AZD0530 on 12-month reductions in 18F-FDG PET measurements of the cerebral metabolic rate for glucose (CMRgl) using statistical parametric mapping (SPM) statistical region of in ) has not been met published in the JAMA Neurology
- 22 Jul 2019 Results assessing effect of AZD0530 on cerebral metabolic decline in Alzheimer disease published in the JAMA Neurology
- 27 Jun 2018 Status changed from active, no longer recruiting to completed.